Insider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 21,119 Shares of Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 21,119 shares of the stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $2.36, for a total transaction of $49,840.84. Following the completion of the transaction, the insider now owns 464,582 shares in the company, valued at $1,096,413.52. This represents a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

John Nuss also recently made the following trade(s):

• On Thursday, December 19th, John Nuss sold 13,161 shares of Ventyx Biosciences stock. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86.

Ventyx Biosciences Trading Down 6.3 %

Shares of NASDAQ VTYX traded down $0.15 during midday trading on Monday, reaching $2.23. 1,563,354 shares of the company were exchanged, compared to its average volume of 2,039,950. The stock has a fifty day simple moving average of $2.29 and a 200 day simple moving average of $2.31. The stock has a market cap of $157.69 million, a P/E ratio of -0.94 and a beta of 0.48. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences during the third quarter worth $26,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences during the third quarter worth about $42,000. The Manufacturers Life Insurance Company raised its holdings in Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ventyx Biosciences in the second quarter valued at about $58,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on VTYX shares. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.